| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 48,555 | 77,159 | ||
| Marketable securities | 256,508 | 216,066 | ||
| Prepaid expenses and other current assets | 7,314 | 10,062 | ||
| Total current assets | 312,377 | 303,287 | ||
| Marketable securities, long-term | 67,165 | 123,806 | ||
| Total property and equipment | 36,216 | - | ||
| Less accumulated depreciation and amortization | 20,063 | - | ||
| Property and equipment, net | 16,153 | 17,505 | ||
| Operating lease right-of-use assets, net | 18,907 | 19,649 | ||
| Other assets | 9,380 | 9,390 | ||
| Total assets | 423,982 | 473,637 | ||
| Accounts payable | 6,863 | 8,700 | ||
| Accrued and other current liabilities | 24,189 | 19,190 | ||
| Deferred revenue | 360 | 1,066 | ||
| Operating lease liabilities, current portion | 5,695 | 5,721 | ||
| Total current liabilities | 37,107 | 34,677 | ||
| Deferred revenue, net of current portion | 835 | 219 | ||
| Derivative liability | 345 | 334 | ||
| Operating lease liabilities, long-term portion | 16,568 | 17,356 | ||
| Other liabilities | 144 | 161 | ||
| Total liabilities | 54,999 | 52,747 | ||
| Common stock, 0.0001 par value, 300,000,000 shares authorized at september 30, 2025 and december 31, 2024 46,771,185 and 45,793,942 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 5 | 5 | ||
| Additional paid-in-capital | 1,104,008 | 1,099,373 | ||
| Accumulated other comprehensive gain | 671 | 337 | ||
| Accumulated deficit | -735,701 | -678,825 | ||
| Total stockholders equity | 368,983 | 420,890 | ||
| Total liabilities and stockholders equity | 423,982 | 473,637 | ||
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)